Whalesbook
Torrent Pharmaceuticals' proposed merger with J.B. Chemicals & Pharmaceuticals Ltd has reached a significant stage. The National Company Law Tribunal (NCLT), Ahmedabad Bench, has uploaded an order concerning the first motion application for the amalgamation. This development signals substantial progress in the merger process, which has an approximate equity valuation of ₹25,689 crore.
Torrent Pharmaceuticals reported Q3 FY26 revenue of ₹3,303 crore.
Torrent Pharmaceuticals informed stock exchanges on March 24, 2026, that the NCLT's Ahmedabad Bench uploaded an order on March 23, 2026. This order relates to the first motion application filed for merging J.B. Chemicals & Pharmaceuticals Limited (JBCPL) into Torrent Pharmaceuticals. The company had initially announced this amalgamation proposal on June 29, 2025.
This NCLT order is a key procedural advancement towards completing the amalgamation. The merger is set to create a larger, integrated pharmaceutical entity by combining the strengths of both companies. It is expected to enhance Torrent Pharmaceuticals' market share and operational efficiencies.
The path to amalgamation began with Torrent Pharma's acquisition of a controlling stake in JBCPL. Announced in June 2025, the deal valued JBCPL at ₹25,689 crore. This involved Torrent acquiring a 46.39% stake from KKR for approximately ₹11,917 crore. The merger is structured in two phases, with JBCPL merging into Torrent Pharma based on a share swap ratio of 51 Torrent shares for every 100 JBCPL shares. The combined entity is projected to have revenues exceeding ₹15,000 crore and EBITDA over ₹4,800 crore, based on FY25 pro forma figures, positioning Torrent Pharma as one of India's largest pharmaceutical companies.
Following the amalgamation, JBCPL's operations will be integrated into Torrent Pharmaceuticals, creating a unified business structure and a stronger market position in India. Torrent Pharma will also gain access to JBCPL's brands in chronic therapy areas and expand into new segments like ophthalmology. JBCPL shareholders will receive Torrent Pharma shares according to the approved swap ratio.
Several regulatory approvals are still required, including clearances from SEBI, CCI, and stock exchanges. The integration of two distinct corporate cultures and operational systems may also present challenges. Additionally, J.B. Chemicals & Pharmaceuticals recently received a ₹80.81 crore GST penalty order, although the company plans to appeal. JBCPL also initiated a voluntary recall of certain tablets in the US market due to an imprinting error, which was classified as a low-risk event.
Torrent Pharmaceuticals and J.B. Chemicals & Pharmaceuticals operate in a competitive market against major players like Sun Pharmaceutical Industries, Cipla, Dr. Reddy's Laboratories, and Zydus Lifesciences. This amalgamation aims to create a stronger competitor with an expanded market reach.
Key figures include the total equity valuation of ₹25,689 crore for J.B. Chemicals & Pharmaceuticals as of June 2025. Torrent Pharmaceuticals reported consolidated revenue of ₹3,303 crore for the quarter ended March 31, 2026. J.B. Chemicals & Pharmaceuticals had a market capitalization of approximately ₹33,442 crore as of March 22, 2026.
Investors will be tracking the remaining regulatory approvals, the progress of integrating JBCPL's operations, and the financial performance of the merged entity.